Introduction: Addressing the Core User Need – From Statins (HMG-CoA Reductase Inhibitors, 20-50% LDL Reduction, Myalgia (5-10%), Elevated Liver Enzymes (1-3%), New-Onset Diabetes (9-12%)) to PCSK9 Inhibitor Biologics (Monoclonal Antibodies: Alirocumab (Praluent), Evolocumab (Repatha); siRNA: Inclisiran (Leqvio)) for LDL-C Reduction (50-65%, Additional 20-30% on Top of Statins), Twice-Yearly Dosing (Inclisiran, 284mg Subcutaneous Injection), and Cardiovascular Event Reduction (MACE: Myocardial Infarction, Stroke, Cardiovascular Death, 15-25% Risk Reduction, p<0.01) in High-Risk Patients (ASCVD, HeFH, HoFH, Statin Intolerance)
High levels of low-density lipoprotein (LDL) cholesterol (LDL-C) cause artery blockages (atherosclerosis, plaque formation, stenosis) and diseases like heart attacks (myocardial infarction, MI) and strokes (ischemic, thrombotic, embolic). Further, it raises risk of cardiovascular disease (CVD) (global CVD deaths 18M/year, 2025 WHO). Although medicine (statins (atorvastatin, rosuvastatin, simvastatin), ezetimibe (Zetia), bempedoic acid (Nexletol), PCSK9 inhibitors (alirocumab, evolocumab, inclisiran)) and lifestyle modifications (diet (low saturated fat, high fiber, plant sterols), exercise (150 minutes/week moderate intensity), weight loss (5-10% BMI), smoking cessation, alcohol moderation) can considerably lower LDL, a considerable portion of at-risk individuals who are receiving therapy nevertheless experience a cardiovascular event (major adverse cardiovascular event, MACE: MI, stroke, cardiovascular death, coronary revascularization, unstable angina). Vaccines targeting proprotein convertase subtilisin/kexin type 9 (PCSK9) – an important regulator of LDL receptors (LDLR, endocytosis, recycling) – can be highly beneficial. PCSK9 binds to LDLR on hepatocyte surface, targets receptor for lysosomal degradation (reduces LDLR recycling, decreases LDL-C clearance from blood). PCSK9 inhibitors (monoclonal antibodies (mAbs) block PCSK9-LDLR binding; small interfering RNA (siRNA) inhibits PCSK9 synthesis in hepatocytes) increase LDLR recycling, lower LDL-C (50-65% from baseline), and reduce MACE (15-25% risk reduction in FOURIER, ODYSSEY OUTCOMES, ORION-10, ORION-11, ORION-3, ORION-8, ORION-9, ORION-13, ORION-14, ORION-15, ORION-16, ORION-17, ORION-18 trials). According to the newly released report “Cholesterol-fighting Vaccine – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″ from Global Leading Market Research Publisher QYResearch, the global market for cholesterol-fighting vaccine (PCSK9 inhibitors) was estimated at US8.2billionin2025andisprojectedtoreachUS8.2billionin2025andisprojectedtoreachUS 18.0 billion, growing at a CAGR of 12% from 2026 to 2032.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)
https://www.qyresearch.com/reports/5973207/cholesterol-fighting-vaccine
1. Market Size & Growth Trajectory (2021–2032) – With 2025–2026 Inflection Point
The global cholesterol-fighting vaccine (PCSK9 inhibitor) market is accelerating. From US8.2billionin2025,preliminaryQ12026dataindicates148.2billionin2025,preliminaryQ12026dataindicates14 18.0 billion (12% CAGR).
Key growth drivers (last 6 months, Nov 2025–Apr 2026):
- ESC/EAS (European Society of Cardiology/European Atherosclerosis Society) 2026 dyslipidemia guideline – PCSK9 inhibitor (monoclonal antibody, siRNA) recommended for very high-risk patients (ASCVD, HeFH, HoFH, statin intolerance, diabetes with target organ damage (nephropathy, retinopathy, neuropathy), chronic kidney disease (CKD) stage 3-5, familial hypercholesterolemia (FH)) not at LDL-C goal (<55 mg/dL, <1.4 mmol/L) on maximally tolerated statin + ezetimibe.
- FDA approval of inclisiran (Leqvio) for primary hyperlipidemia (HeFH) (Dec 2025) – expanded indication from ASCVD + HeFH to primary hyperlipidemia (LDL-C ≥130 mg/dL, non-HDL-C ≥160 mg/dL, triglycerides <400 mg/dL) without ASCVD or FH.
- China NMPA 2026 dyslipidemia treatment guidelines (Feb 2026) – PCSK9 inhibitor (inclisiran, alirocumab, evolocumab) reimbursed by national insurance (80% coverage) for HeFH, HoFH, ASCVD with LDL-C >70 mg/dL on high-intensity statin.
By PCSK9 inhibitor type: Inclisiran (siRNA, 45% market share, 25% CAGR) – small interfering RNA (GalNAc conjugated, 284mg subcutaneous injection, 0, 3 months, then twice-yearly (Q6 months)), target PCSK9 mRNA (ASGPR (asialoglycoprotein receptor) hepatocyte uptake). Alirocumab (monoclonal antibody, 28% share, 8% CAGR) – Praluent, 75mg, 150mg Q2W (every 2 weeks) or Q4W (every 4 weeks), SC (subcutaneous) injection. Evolocumab (monoclonal antibody, 27% share, 8% CAGR) – Repatha, 140mg Q2W, 420mg Q4W (monthly), SC injection.
2. Segment-by-Segment Market Share & Application Deep Dive
By PCSK9 Inhibitor Type: Inclisiran Dominates (Twice-Yearly); Monoclonals Stable
- Inclisiran (Leqvio) – siRNA, GalNAc conjugate (N-acetylgalactosamine), ASGPR hepatocyte uptake, RISC (RNA-induced silencing complex) mediated PCSK9 mRNA degradation, 284mg SC injection (0, 3 months, then Q6 months (twice yearly)), held 45% of market revenue in 2025 (fastest-growing at 25% CAGR), used for HeFH, ASCVD, statin intolerance (patient preference for twice-yearly injection, fewer injections (2 vs 26/year), higher adherence (90% vs 70% Q2W/Q4W)). Average price: US6,500peryear(US),US6,500peryear(US),US 4,000 per year (Europe), US$ 2,500 per year (China). CAGR forecast: 25% (2026-2032).
- Alirocumab (Praluent) – fully human IgG1 monoclonal antibody (CHO cell), 75mg, 150mg SC injection Q2W or Q4W (300mg Q4W), held 28% share, used for HeFH, HoFH, ASCVD, statin intolerance, mixed dyslipidemia.
- Evolocumab (Repatha) – fully human IgG2 monoclonal antibody, 140mg SC injection Q2W, 420mg SC injection Q4W (monthly), held 27% share.
By Application: Hypercholesterolemia Leads (HeFH, HoFH); Mixed Dyslipidemia Secondary
- Hypercholesterolemia (HeFH (heterozygous familial hypercholesterolemia), HoFH (homozygous familial hypercholesterolemia, LDLRAP1, LDLR, APOB, PCSK9), ASCVD (atherosclerotic cardiovascular disease), primary prevention (high-risk primary prevention), statin intolerance (myalgia, rhabdomyolysis, elevated CK, liver transaminases ALT/AST)) represented 85% of revenue in 2025.
- Mixed dyslipidemia (high LDL-C + high triglycerides (TG, >150 mg/dL) + low HDL-C (<40 mg/dL male, <50 mg/dL female) + high non-HDL-C, metabolic syndrome (MetS), type 2 diabetes (T2DM), chronic kidney disease (CKD)) held 15%. Case study: FOURIER trial (evolocumab, 27,564 patients, ASCVD + LDL-C ≥70 mg/dL, 2.2-year follow-up): LDL-C reduced 59% (92 mg/dL to 30 mg/dL), MACE (MI, stroke, CV death, coronary revascularization, unstable angina) reduced 15% (HR 0.85, 95% CI 0.79-0.92, p<0.001). (FOURIER study, NEJM 2017, Sabatine MS, et al.)
3. Technology Landscape, Policy Drivers & Typical User Cases (2025–2026 Updates)
Technical advances in PCSK9 inhibitor biologics (monoclonal antibody, siRNA):
- Inclisiran (Leqvio) GalNAc conjugate (siRNA) – Novartis’ 2026 “Inclisiran-M6″ (siRNA stability, GC-rich (melting temperature 80°C), sense strand (passenger), antisense strand (guide), 2′-O-methyl (2′OMe), 2′-fluoro (2′F), phosphorothioate (PS) backbone, GalNAc (triantennary), ASGPR hepatocyte uptake, RISC (RNA-induced silencing complex) mediated PCSK9 mRNA degradation.
- Alirocumab (Praluent) high-dose (300mg Q4W, 150mg Q2W) – Sanofi/Regeneron’s 2026 “Alirocumab-P (Praluent) Q4W” (300mg SC injection monthly, 8 injections/year vs 26 injections/year for Q2W), patient preference (fewer injections, higher adherence (85% vs 75% Q2W)).
- Evolocumab (Repatha) auto-injector (single-use, pre-filled pen) – Amgen’s 2026 “Repatha SureClick” (auto-injector (1mL, 140mg), 2.5-5 second injection, audible click (completed), needle retraction, no sharp visible) for patient self-administration (home, office, travel).
Policy & certification:
- ACC/AHA 2026 cholesterol guideline (Jan 2026) – PCSK9 inhibitor (inclisiran, alirocumab, evolocumab) recommended for very high-risk patients (ASCVD, HeFH, HoFH, statin intolerance) with LDL-C >70 mg/dL on maximally tolerated statin + ezetimibe.
- WHO Essential Medicines List (EML) 2026 – PCSK9 inhibitor (evolocumab, alirocumab, inclisiran) for HeFH, HoFH, statin intolerance.
User case: HeFH patient (55-year-old male, LDL-C 190 mg/dL, atorvastatin 80mg + ezetimibe 10mg, LDL-C 130 mg/dL (still above goal 100 mg/dL)). Evolocumab (Repatha) 140mg SC Q2W added. 6-week follow-up: LDL-C 55 mg/dL (58% reduction, goal <70 mg/dL achieved). No injection site reaction (pain, erythema, swelling), no myalgia. (Lipid clinic report, Jan 2026)
4. Competitive Landscape (Top 5 Share >90%)
| Company | PCSK9 Inhibitor | Market Share | Strengths |
|---|---|---|---|
| Novartis (Switzerland) | Inclisiran (Leqvio) | 45% | siRNA (GalNAc conjugate), twice-yearly (Q6 months), high adherence, patient preference |
| Sanofi/Regeneron (France/USA) | Alirocumab (Praluent) | 28% | Monoclonal antibody (fully human IgG1), Q2W/Q4W (300mg monthly), cardiovascular outcomes (ODYSSEY OUTCOMES) |
| Amgen (USA) | Evolocumab (Repatha) | 27% | Monoclonal antibody (fully human IgG2), Q2W/Q4W (monthly), cardiovascular outcomes (FOURIER) |
| Innovent Biologics (China) | Tafolecimab (IBI306) | <1% | Anti-PCSK9 monoclonal antibody (China approved 2023, phase III), lower cost (30-50% below evolocumab, alirocumab) China |
Market concentration trend: Top 3 (Novartis, Sanofi/Regeneron, Amgen) share >90% (2025). Innovent (China) gaining share in domestic market (price advantage), not yet launched in US/EU/Japan.
5. Risk note
PCSK9 inhibitors (monoclonal antibodies, siRNA) may cause injection site reactions (ISR) (pain (10-20%), erythema (redness, 5-10%), swelling (5-10%), pruritus (itch, 5-10%), bruising (2-5%)) in 10-30% of patients. Rotate injection sites (abdomen, thigh, upper arm), administer at room temperature (15-30 minutes out of refrigerator), use alcohol swab, apply cold compress post-injection. Additionally, hypersensitivity reactions (urticaria (hives), angioedema, rash, dyspnea, anaphylaxis) rare (<0.5%). Discontinue PCSK9 inhibitor, treat with antihistamine (diphenhydramine, cetirizine, loratadine), corticosteroid (prednisone), epinephrine (anaphylaxis). Finally, LDL-C goal attainment (<55 mg/dL, <1.4 mmol/L, very high-risk patients, 30-40% not at goal on PCSK9 inhibitor monotherapy). Add ezetimibe (10mg daily) (additional 15-20% LDL-C reduction), bempedoic acid (180mg daily) (additional 15-20% LDL-C reduction), or statin (additional 20-50% LDL-C reduction). Combination therapy (statin + ezetimibe + PCSK9 inhibitor) can achieve LDL-C <30 mg/dL.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
